PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

PAG makes $200m investment in RK Pharma

Hong Kong-based private equity firm PAG is to make an investment of up to $200 million in RK Pharma Inc, a vertically integrated pharmaceutical company based in the US with subsidiaries in India. Terms of the deal have not been disclosed.

Hong Kong-based private equity firm PAG is to make an investment of up to $200 million in RK Pharma Inc, a vertically integrated pharmaceutical company based in the US with subsidiaries in India. Terms of the deal have not been disclosed.

RK Pharma is focused in the development, manufacture and sale of generic pharmaceutical products with a particular focus on complex injectables. The company, which has a Sterile Drug Product Manufacturing facility in Pearl River, New York, USA, owns several subsidiaries including: Apicore, Archis Pharma and Aktinos Pharma. A

RK Pharma is PAG’s fifth India-focused private equity deal in recent years. Other notable investments include Nuvama, India’s second largest independent wealth manager; Gamot API, a platform for investing in leading active pharmaceutical ingredient (API) companies; and Acme Formulation, a leader in contract development and manufacturing outsourcing (CDMO) pharmaceuticals. PAG has invested more than USD1.5 billion in India in the last few years.

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured